Sign in
Not yet recruitingPhase 2

Colchicine to Prevent Long-Term Leg Problems After Deep Vein Thrombosis

Tests colchicine against placebo in adults with deep vein thrombosis in the leg.

Key facts

Who runs it
Universita' Degli Studi G. D'Annunzio Di Chieti
Where
Italy5 sites in 1 countryChoose a country to see its sites
Registry title
Study on the use of colchicine to reduce inflammation after deep vein thrombosis
Status
Not yet recruiting
Phase
Phase 2
People taking part
122 people, planned
Started
2 Feb 2026
Expected to end
2 Aug 2028
Type of study
Interventional
Record updated
8 June 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with a first, sudden blood clot in a deep vein of the leg, at or above the knee. It tests whether colchicine 0.5 mg daily lowers the risk of post-thrombotic syndrome (long-term leg pain and swelling) compared with placebo.

Age
18 years or older
Sex
All sexes
Disease stage
First, acute deep vein thrombosis with symptoms, in the popliteal vein (behind the knee) or higher in the leg, confirmed by a test.
Earlier treatment
People who recently (<30 days) or regularly used immunosuppressive drugs by mouth or vein (such as steroids, tumor necrosis factor-alpha blockers, cyclosporine) cannot join. People who need colchicine for another reason cannot join.

Main reasons for not taking part

  • Known active cancer, HIV infection, or a recent (<30 days) or active infection
  • Liver problems: ALT or AST >3x upper limit of normal, bilirubin >2x upper limit of normal, cirrhosis or severe liver disease
  • Creatinine clearance <30 mL/min (poor kidney function)
  • Pregnancy, breastfeeding, or women able to have children who will not use birth control
  • Chronic diarrhoea, inflammatory bowel disease, blood disorders, colchicine allergy, or drugs that interact with colchicine such as erythromycin or clarithromycin

The registry criteria, word for word

Show all 18 criteriaShow less

Who can take part

  • 18 years of age or older
  • First, acute, symptomatic proximal (popliteal or more proximal vein) objectively-confirmed DVT of the lower extremity
  • Written informed consent

Who cannot take part

  • Participation in another interventional trial within the past 30 days or 5 half-lives of the study drug, whichever is longer
  • Use of medications with known significant drug-to-drug interactions with colchicine including but not limited to erythromycin or clarithromycin
  • Recent (<30 days) or chronic use of systemic (oral, intravenous) immunosuppressive drugs (including but not limited to steroids, tumor necrosis factor-alpha blockers, cyclosporine)
  • Known active cancer
  • Presence of HIV infection
  • Hypersensitivity to the active substance or to any of the excipients
  • History of an allergic reaction or significant sensitivity to colchicine
  • Active or chronic diarrhoea, or documented inflammatory bowel disease (i.e., Crohn’s disease or ulcerative colitis), collagenous colitis/irritable bowel syndrome, or existing blood dyscrasias
  • Known or suspected, recent (<30 days) or active infections (acute or chronic)
  • History of cirrhosis, chronic active hepatitis, or severe liver disease
  • Any of the following as measured within the past 1-3 months or at screening: alanine or aspartate aminotransferase >3x upper limit of normal (ULN); total bilirubin >2x ULN; creatinine clearance, calculated using Cockcroft-Gault formula, <30 mL/min
  • Any contraindication to colchicine as per summary of product characteristics (SmPC)
  • Unwilling to provide consent
  • Pregnancy, breastfeeding or may be considering pregnancy during the study period or women of childbearing potential unwilling to use appropriate contraception during sex
  • Requirement of colchicine for other indications

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

To evaluate the safety and efficacy of low-dose colchicine 0.5 mg versus placebo once daily in reducing the risk of Post-thrombotic syndrome (PTS) in patients with proximal lower-extremity deep vein thrombosis (DVT).

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
Colchicine to Quench the Inflammatory Response after Deep Vein Thrombosis: The CONQUER-DVT Randomized Controlled Trial
Plain-language title
Colchicine to Prevent Long-Term Leg Problems After Deep Vein ThrombosisGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 15 November 2026.
Record updated
8 June 2026